MedTrace Logo

Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain

NCT01207596 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-06-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out if Exalgo (r) is beneficial for the patients with neuropathic pain.

Conditions

  • Neuropathic Pain

Interventions

DRUG

Hydromorphone

Oral hydromorphone extended release, once daily

Sponsors & Collaborators

  • International Clinical Research Institute

    lead OTHER

Principal Investigators

  • Srinivas Nalamachu, MD · International Clinical Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01207596 on ClinicalTrials.gov